This has probably been posted before but just in case:
CONCLUSIONS
This study is important for several reasons. First, there is a desperate need for the development of novel schizophrenia treatments with innovative mechanisms of action that target clinically significant negative symptoms and cognitive impairment. All currently available drugs for monotherapy of schizophrenia bind to the dopamine D2 receptor, and an agent that is meant to block both 5-HT2A and sigma-2 receptors represents a potentially important new strategy. Second, very few studies have demonstrated meaningful correlated improvements in negative symptoms and cognitive deficits resulting from pharmacotherapy. Finally, since there are no available treatments for cognitive impairment or negative symptoms in schizophrenia, the current results that MIN-101 provides benefit for both of these aspects of schizophrenia suggest the potential to alleviate 2 significant unmet needs.